Skip to main navigation Skip to main content Skip to footer For Medicare For Providers For Brokers For Employers Español For Individuals & Families: For Individuals & Families Medical Dental Other Supplemental Explore coverage through work How to Buy Health Insurance Types of Dental Insurance Open Enrollment vs. Special Enrollment See all topics Shop for Medicare plans Member Guide Find a Doctor Log in to myCigna
Home Knowledge Center Wellness Library molnupiravir

molnupiravir

What is the most important information I should know about molnupiravir?

The US Food and Drug Administration (FDA) has authorized emergency use of molnupiravir for the treatment of mild-to-moderate COVID-19 in people 18 years of age and older.

What is molnupiravir?

What is molnupiravir?

Molnupiravir is an experimental medicine being studied for the treatment of mild-to-moderate COVID-19. This drug is still being studied and all of its risks are not yet known.

The US Food and Drug Administration (FDA) has authorized emergency use of molnupiravir for the treatment of mild-to-moderate COVID-19 in people 18 years of age and older:

  • testing positive for COVID-19;
  • who are at high risk for progression to severe COVID-19, including hospitalization or death; and
  • for whom other COVID-19 treatment options are not available or applicable.

Molnupiravir is not authorized for use:

  • for initiation of treatment in people needing hospitalization due to COVID-19;
  • for prevention before or after exposure of COVID-19; or
  • longer than 5 consecutive days.

Molnupiravir may also be used for purposes not listed in this medication guide.

What should I discuss with my healthcare provider before taking molnupiravir?

What should I discuss with my healthcare provider before taking molnupiravir?

Tell your doctor if you have any serious or chronic disease.

Molnupiravir may harm an unborn baby if the mother or father is using this medicine:

  • If you are a woman, do not use molnupiravir if you are pregnant. Use effective birth control to prevent pregnancy while you are using this medicine and for at least 4 days after your last dose.
  • If you are a man, use an effective birth control if your sex partner is pregnant or is able to get pregnant. Keep using birth control for at least 3 months after your last dose.
  • Tell your doctor right away if a pregnancy occurs while either the mother or the father is using molnupiravir.

You may need to have a negative pregnancy test before starting this treatment.

If you are pregnant, your name may be listed on a pregnancy registry to track the effects of molnupiravir on the baby.

Do not breastfeed while using this medicine, and for at least 4 days after your last dose. If you use a breast pump during this time, throw out any milk you collect. Do not feed it to your baby.

Not approved for use by anyone younger than 18 years old.

How should I take molnupiravir?

How should I take molnupiravir?

Follow all directions on your prescription label and read all medication guides or instruction sheets. Use the medicine exactly as directed.

Take molnupiravir (four capsules) every 12 hours for 5 consecutive days.

Take this medicine as soon as possible after diagnosis of COVID-19 and within 5 days of when symptoms first appear.

You may take molnupiravir with or without food.

Swallow the capsule whole and do not crush, chew, break, or open it.

Being treated with molnupiravir will not make you less contagious to other people. Keep using infection control methods such as self-isolation, social distancing, hand-washing, using protective face covering, disinfecting surfaces you touch a lot, and not sharing personal items with others.

Molnupiravir is still being studied and all of the risks are not yet known.

What happens if I miss a dose?

What happens if I miss a dose?

Use the medicine as soon as you can, but skip the missed dose if you are more than 10 hours late for the dose. Do not use two doses at one time.

What happens if I overdose?

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while taking molnupiravir?

What should I avoid while taking molnupiravir?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

What are the possible side effects of molnupiravir?

What are the possible side effects of molnupiravir?

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor if you have any new or worsening symptoms.

Common side effects may include:

  • diarrhea, nausea; or
  • dizziness.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect molnupiravir?

What other drugs will affect molnupiravir?

Other drugs may affect molnupiravir, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

Where can I get more information?

Where can I get more information?

Your doctor or pharmacist can provide more information about molnupiravir.

This information does not replace the advice of a doctor. Healthwise, Incorporated, disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. Learn how we develop our content.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.

<cipublic-spinner variant="large"><span>Loading…</span></cipublic-spinner>

Page Footer

I want to...

Get an ID card File a claim View my claims and EOBs Check coverage under my plan See prescription drug list Find an in-network doctor, dentist, or facility Find a form Find 1095-B tax form information View the Cigna Glossary Contact Cigna

Audiences

Individuals and Families Medicare Employers Brokers Providers

Secure Member Sites

myCigna member portal Health Care Provider portal Cigna for Employers Client Resource Portal Cigna for Brokers

Cigna Company Information

About Cigna Company Profile Careers Newsroom Investors Suppliers Third Party Administrators International Evernorth

 Cigna. All rights reserved.

Privacy Legal Product Disclosures Cigna Company Names Customer Rights Accessibility Non-Discrimination Notice [PDF] Language Assistance [PDF] Report Fraud Sitemap

Disclaimer

Individual and family medical and dental insurance plans are insured by Cigna Health and Life Insurance Company (CHLIC), Cigna HealthCare of Arizona, Inc., Cigna HealthCare of Illinois, Inc., and Cigna HealthCare of North Carolina, Inc. Group health insurance and health benefit plans are insured or administered by CHLIC, Connecticut General Life Insurance Company (CGLIC), or their affiliates (see a listing of the legal entities  that insure or administer group HMO, dental HMO, and other products or services in your state). Accidental Injury, Critical Illness, and Hospital Care plans or insurance policies are distributed exclusively by or through operating subsidiaries of Cigna Corporation, are administered by Cigna Health and Life Insurance Company, and are insured by either (i) Cigna Health and Life Insurance Company (Bloomfield, CT); (ii) Life Insurance Company of North America (“LINA”) (Philadelphia, PA); or (iii) New York Life Group Insurance Company of NY (“NYLGICNY”) (New York, NY), formerly known as Cigna Life Insurance Company of New York. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. LINA and NYLGICNY are not affiliates of Cigna.

All insurance policies and group benefit plans contain exclusions and limitations. For availability, costs and complete details of coverage, contact a licensed agent or Cigna sales representative. This website is not intended for residents of New Mexico.

Selecting these links will take you away from Cigna.com to another website, which may be a non-Cigna website. Cigna may not control the content or links of non-Cigna websites. Details